Patents by Inventor Marie-Pierre Dube

Marie-Pierre Dube has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210290623
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 23, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Publication number: 20210236442
    Abstract: The invention provides compositions and methods useful for delaying occurrence of new-onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 5, 2021
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Fouzia LAGHRISSI-THODE
  • Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20200239960
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 27, 2020
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20200222406
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 10584385
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: March 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20190070178
    Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 7, 2019
    Inventors: Marie-Pierre DUBÉ, Jean-Claude TARDIF, Eric RHÉAUME
  • Publication number: 20180155784
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20170233812
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: January 25, 2017
    Publication date: August 17, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20160244826
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 25, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Publication number: 20160230231
    Abstract: The invention relates to genetic variants useful for evaluating creatine kinase levels in a subject and determining an Nupper limit of normal (ULN) CK level for a subject. ULN CK level is used in determining the pathological significance of measures of blood or plasma CK obtained from the subject. The methods and compositions of the invention are useful for providing a genetic-C ally determined or individualized ULN CK level, for diagnosing statin-induced myopathy and for providing statin therapy.
    Type: Application
    Filed: October 17, 2014
    Publication date: August 11, 2016
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Patent number: 8563241
    Abstract: There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: October 22, 2013
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Marie-Pierre Dubé, Hannah Beattie
  • Patent number: 8334369
    Abstract: The invention relates to polynucleotides and polypeptides which encode UBIAD1.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: December 18, 2012
    Assignee: Genome Atlantic
    Inventors: Mark Elliot Samuels, Duane Guernsey, Marie-Pierre Dube, Andrew C. Orr
  • Publication number: 20100304393
    Abstract: There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 2, 2010
    Inventors: Marie-Pierre Dubé, Hannah Beattie
  • Publication number: 20100190161
    Abstract: The invention relates to polynucleotides and polypeptides which encode UBIAD1.
    Type: Application
    Filed: February 6, 2008
    Publication date: July 29, 2010
    Inventors: Mark Elliot Samuels, Duane Guernsey, Marie-Pierre Dube, Andrew C. Orr
  • Patent number: 7734656
    Abstract: A method for conducting genetic research on medical data. The method includes the step of accessing a database storing a plurality of medical records associated with a plurality of individuals, each medical record including at least one unique identifier associated with a certain individual and medical data associated with the certain individual. The method also includes the steps of extracting from the database the medical data associated with at least a subset of the plurality of individuals and, for each individual of the subset, obtaining electronically stored genetic data associated with the respective unique identifier. Also, the method includes processing the extracted medical data and obtained genetic data for attempting to identify an association between particular genetic data and a particular medical condition.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: June 8, 2010
    Inventors: Luc Bessette, Marie-Pierre Dubé
  • Publication number: 20060166207
    Abstract: Methods of utilizing a gene related to pain perception, herein dubbed HSN2, or its encoded protein, dubbed herein “sensorin,” for the screening and identification of agents for the treatment of pain, neuropathy and related disorders, especially small organic compounds, as well as methods of using these compounds to treat or otherwise ameliorate pain, neuropathy and related disorders in human patients. Novel polypeptides and polynucleotides, along with their nucleotide and amino acid sequences, are also disclosed.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 27, 2006
    Inventors: Ronald Lafreniere, Marie-Pierre Dube, Marcia MacDonald, Mark Samuels